CLEVELAND, July 11, 2018 /PRNewswire/
-- ViewRay, Inc. (Nasdaq: VRAY) announced that the
company's MRIdian® Linac has been selected for installation at
Centre Georges-François Leclerc (CGFL) in Dijon, France as
part of a tender award contract with UNICANCER, a hospital network
of 19 French Comprehensive Cancer Centers (FCCCs).
MRIdian Linac combines the latest innovations in precision
radiation delivery with ground-breaking MR image guidance. It
enables daily real-time on-table adaptive radiotherapy (ROAR™)
treatment, allowing clinicians to quickly and dynamically adjust
for anatomical changes that may naturally occur each day throughout
the patient's course of treatment. The technology also allows
oncologists to visualize and actively track the unique contours of
the tumor and surrounding organs during radiation delivery using a
non-ionizing, streaming video perspective. Combined, these
capabilities provide the clinicians with the tools to potentially
improve tumor targeting precision and thus allow for delivery of
higher, and potentially more effective, radiation doses.
UNICANCER is the only French hospital federation exclusively
dedicated to oncology and the leading academic promoter of oncology
clinical trials in Europe. Its
FCCCs are private, non-profit hospitals that guarantee the same
quality of care across institutions and allow for quick and secure
access to innovations in the areas of care and research.
"We carefully evaluated the options for MR-guided radiation
therapy in Europe and selected
MRIdian Linac for its combination of high-fidelity beam delivery
and ability to deliver advanced SBRT," said Professor Charles Coutant, General Manager of CGFL.
"MRIdian Linac's ability to deliver adaptive radiotherapy helps
us overcome challenges like real-time anatomical movement and
day-to-day changes in the shape, size or location of the tumor,
which should allow for better targeting accuracy and sparing of
nearby organs and healthy tissue," said Karine Peignaux, M.D., Head
of Radiation Therapy at CGFL.
"By integrating MRI with a Linac, ViewRay has foreseen the
future of external radiotherapy, which is linked to improvements in
target and organ definition based on the anatomy of the day using
MRI," said Professor Gilles
Créhange, Head of Clinical R&D, Radiation Therapy at
CGFL. "Targeting cancer and delivering radiation under real-time
MRI guidance should improve treatment with the potential for lower
rates of toxicity."
About ViewRay®
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets
the MRIdian® radiation therapy system. MRIdian is built upon a
proprietary high-definition MR imaging system designed from the
ground up to address the unique challenges and clinical workflow
for advanced radiation oncology. Unlike MR systems used in
diagnostic radiology, MRIdian's high-definition MR was purpose
built to address specific challenges, including beam distortion,
skin toxicity, and other concerns that may potentially arise when
high magnetic fields interact with radiation beams. ViewRay and
MRIdian are registered trademarks of ViewRay, Inc.
This press release contains forward-looking statements.
Statements in this press release that are not purely historical are
forward-looking statements. These statements are subject to risks
and uncertainties that could cause future results to differ
materially from those referenced. Forward looking statements
include the advancement of science, and the ability of MRI-guided
radiation therapy programs to enable more treatment options,
improved tumor targeting precision and higher, more effective,
radiation dose. Given these uncertainties, the reader is advised
not to place any undue reliance on any forward-looking statements.
Additional risk factors include, among others, the ability to raise
the additional funding needed to continue to pursue ViewRay's
business and product development plans, the inherent uncertainties
associated with developing new products or technologies,
competition in the industry in which ViewRay operates and overall
market conditions. These forward-looking statements are made as of
the date of this press release, and ViewRay assumes no obligation
to update the forward-looking statements, or to update the reasons
why actual results differ from those projected in the
forward-looking statements, except as required by law. Investors
should consult all of the information set forth herein and should
also refer to the risk factor disclosure set forth in the reports
and other documents ViewRay files with the SEC available at
www.sec.gov.
View original
content:http://www.prnewswire.com/news-releases/viewrays-mridian-linac-awarded-french-tender-for-mr-image-guided-radiation-therapy-300678495.html
SOURCE ViewRay, Inc.